UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

Gilead Sciences

G

Gilead Sciences

BiotechnologyFoster City, United States
Visit Website

About Gilead Sciences

Gilead Sciences transformed the treatment of HIV and hepatitis C, producing antiretroviral regimens now used by tens of millions of people worldwide and a hepatitis C cure that changed the standard of care globally. Founded in 1987 and headquartered in Foster City, California, Gilead is listed on the Nasdaq under the ticker GILD and operates across more than 35 countries, with manufacturing, clinical research, and commercial operations spanning North America, Europe, and Asia.

HIV & Viral Disease Leadership

The company's HIV portfolio includes single-tablet regimens that brought once-complex treatment schedules down to a daily pill, including the widely prescribed Biktarvy and Descovy. Gilead's HIV medicines anchor national treatment guidelines in numerous countries and the company also markets Truvada and Descovy for pre-exposure prophylaxis (PrEP). In viral hepatology, its Sovaldi and Harvoni regimens achieved cure rates above 90 per cent for hepatitis C, redefining what patients and clinicians could expect from antiviral therapy.

Oncology & Expanding Pipeline

Gilead has built a substantial oncology division, accelerated by its acquisition of Kite Pharma in 2017, which brought cell therapy capabilities including the CAR-T treatment Yescarta for certain blood cancers. The subsequent acquisition of Immunomedics added Trodelvy, an antibody-drug conjugate indicated for specific breast and bladder cancers. The company continues to invest in inflammation, lung disease, and emerging infectious diseases, reflecting a broader ambition beyond its original antiviral roots.

Gilead's global access programmes and tiered-pricing agreements with generic manufacturers have extended its HIV medicines to lower-income countries, making it a significant participant in public health efforts coordinated with organisations such as PEPFAR and the Global Fund. The company reports annual revenues in excess of twenty billion US dollars and employs approximately seventeen thousand people worldwide.

Further information is available at gilead.com.

Similar Companies

More in Biotechnology

M

Moderna

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna is a clinical-stage biotechnology company listed on the Nasdaq (ticker: MRNA) that has built its entire operation around a single scientific bet: that messenger RNA can be harnessed as a programmable medicine. Rather than developing one drug at a time, the company operates as an mRNA platform business, using the same underlying technology to generate candidates across vaccines, oncology, rare disease and cardiovascular indications. The mRNA Platform and Pipeline More than fifteen years of continuous mRNA research underpin Moderna's proprietary mRNA Design Studio, a discovery and development environment that allows scientists to design, iterate and optimise mRNA sequences with a speed that conventional small-molecule or biologics programmes cannot match. The platform has already produced two approved products: Spikevax, its COVID-19 vaccine authorised in multiple markets worldwide, and mRESVIA, an mRNA-based vaccine for respiratory syncytial virus approved by the US FDA in 2024 for adults aged 60 and over. A broad pipeline sits behind these approvals, including an investigational seasonal influenza vaccine (mRNA-1010), a personalised cancer vaccine programme developed in collaboration with Merck that uses individualised mRNA sequences to target tumour-specific neoantigens, and candidates targeting cytomegalovirus, latent HIV and rare metabolic disorders. Global Operations and Commercial Scale Moderna maintains country-specific commercial and regulatory operations across North America, Europe and Asia Pacific, with established presences in the United States, Canada, the United Kingdom, France, Germany, Italy, the Netherlands, Spain, Switzerland, Poland, Australia, Japan, South Korea, Hong Kong, Taiwan and Singapore. The company has received substantial non-dilutive funding through longstanding partnerships with US government agencies including BARDA and DARPA, which supported its early platform work. Investor relations, healthcare professional resources, supplier programmes and a clinical trials portal are all maintained as distinct operational functions, consistent with Moderna's scale as a multi-market biopharmaceutical organisation. Further information is available at modernatx.com.

View profile
A

Alacris Theranostics

Alacris Theranostics positions itself as a systems medicine company, delivering integrated next-generation sequencing (NGS) services and bioinformatics solutions designed to translate multi-modal omics data into actionable insights for researchers, pharmaceutical partners and healthcare professionals. Based in Germany, the company's core offering spans the full omics workflow, from NGS data generation through to computational interpretation. Its bioinformatics capability is presented as central to the value proposition, enabling clients to move from raw sequencing output to clinically and scientifically meaningful results without switching vendors or platforms. The company also offers immune repertoire analysis alongside its broader genomics portfolio. A distinctive element of Alacris Theranostics' research and development work is the ModCell digital twin concept, a computational modelling approach aimed at supporting personalised medicine applications. The Alacris-CMTA platform is referenced within this context, reflecting an ambition to connect molecular profiling with precision oncology decision-making. The company's stated mission is to make comprehensive NGS services accessible across the research and pharma sectors, with a declared focus on advancing precision medicine and improving patient outcomes. Its approach emphasises customisation, on the basis that each project and each patient presents distinct challenges that standardised pipelines may not adequately address. Quality management, equality and diversity commitments, and an environmental policy statement are all cited on its public-facing communications, indicating structured internal governance. Further information is available at alacris.de.

View profile
A

AstraZeneca UK

AstraZeneca is one of the world's largest biopharmaceutical companies, with its global headquarters at the Cambridge Biomedical Campus in England. Founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group of the United Kingdom, the company is listed on the London Stock Exchange (AZN) and on Nasdaq, and employs approximately 90,000 people across more than 100 countries. Cambridge functions not merely as a corporate address but as the centre of the company's worldwide research and early development capability, hosting thousands of scientists working across discovery biology, chemistry, and translational medicine. Therapy Areas and Pipeline The company's research strategy concentrates on three main therapy area clusters: oncology, cardiovascular, renal and metabolic disease (CVRM), and respiratory and immunology (R&I). Within oncology, AstraZeneca markets established medicines including osimertinib (Tagrisso), olaparib (Lynparza, developed with MSD), and durvalumab (Imfinzi). The CVRM portfolio includes dapagliflozin (Farxiga/Forxiga), which has received regulatory approvals across heart failure, chronic kidney disease, and type 2 diabetes indications. The respiratory franchise covers budesonide/formoterol combinations and the biologic tezepelumab (Tezspire, developed with Amgen) for severe asthma. UK Operations and Clinical Development AstraZeneca UK operates across the full pharmaceutical value chain: early and late-stage clinical trials, regulatory affairs, medical affairs, market access, and commercial operations serving the National Health Service. The UK site at Cambridge is complemented by manufacturing and biologics development capabilities at sites including Macclesfield. The company collaborates extensively with the Medical Research Council, Cancer Research UK, and NHS England, and was a prominent partner in the University of Oxford COVID-19 vaccine programme, through which AstraZeneca's Vaxzevria was manufactured and distributed globally at no profit during the pandemic period. AstraZeneca participates in hundreds of sponsored clinical studies in the United Kingdom at any given time, engaging NHS trusts, academic medical centres, and independent research sites. The organisation also operates a patient access programme infrastructure and maintains a dedicated UK medical information service for healthcare professionals. Further information is available at astrazeneca.co.uk.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy